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B  cells are produced from B  cell precursors primarily in the bone marrow of adult 
mice (1), but relatively little is known about the differentiation steps that precede the 
appearance  of cells  with  surface  immunoglobulin  (sIg)  1.  A  major  difficulty  with 
elucidating these steps has been the lack of well-defined surface markers which would 
facilitate the identification and isolation of B  cell precursors. The alloantigen Lyb-2 
(2)  is expressed on  B  cells, a  fraction of sIg- bone marrow cells, and some putative 
pre-B  cell  tumors  (3).  Another  B  cell  alloantigen,  Lyb-1  (4),  has  a  similar  tissue 
distribution and,  like Lyb-2, is expressed on  some sIg- bone  marrow  cells. Neither 
antigen, however, has been shown to be on B  cell precursors. 
Current  techniques  for producing monoclonal  antibodies by cell fusion offer the 
prospect of defining new  surface  markers on  B  cell precursors and  preparing large 
quantities of monospecific antibodies to those markers. Such antibodies would make 
possible, for the first time, the enumeration and purification of viable B cell precursors. 
The availability of highly enriched B  cell precursors would permit a  detailed explo- 
ration of early B  cell differentiation at a  cellular and molecular level. To raise such 
antibodies, we have  initiated a  program  to make hybridomas with  rats immunized 
with normal and neoplastic mouse B  and pre-B cells. We report here a  monoclonal 
antibody that recognizes a determinant on B cells and a  fraction of slg- bone marrow 
cells that includes B  cell precursors. 
Materials  and  Methods 
Hybridomas.  A Lewis rat was immunized with four injections of 2 ×  l0  s RAW 112 cells and 
the spleen was harvested 3 d after the last injection. The cells were fused in 38% polyethylene 
glycol with S194/5.XXO.BUol  (bromodeoxyuridine-resistant) mouse myeloma cells and  the 
mixture was plated immediately in hypoxanthine aminopterin thymidine (HAT) medium at 
1.5 ×  106 cells/1.5-ml well. When the hybrids reached a density of at least 2 ×  105 cells/ml, the 
supernatant fluids were harvested and tested for immunofluorescent staining of bone marrow, 
thymus, and RAW 112 cells. RA3-2C2 was selected for further study because it stained RAW 
112 and a subpopulatlon of bone marrow cells but not thymocytes. The cell line was subcloned 
by limiting dilutions before further use. 
Animals.  BALB/c mice and Lewis rats were bred in our own colony. Mice of either sex were 
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used in these experiments at 6-10 wk of age, except the recipient mice for the spleen colony- 
forming unit  (CFU-s) assay, which were 4-6 mo of age. 
Antisera.  Rabbit  anti-#  chain  and  anti-x  antisera  were specifically eluted  from  myeloma 
protein  immunoadsorbent  columns  and  have been  characterized  previously  (5).  Specifically 
eluted rabbit  anti-keyhole limpet hemocyanin  (KLH)  was used as a  control  first stage. Goat 
anti-rabbit Ig was specifically eluted from a rabbit Ig column and conjugated with fluorescein 
isothiocyanate (FITC) to yield a ratio of four fluorescein molecules per molecule of IgG. Rabbit 
anti-rat Ig was passed first through a mouse Ig column to remove cross-reactive antibodies, and 
then eluted from a rat Ig column. It was conjugated with FITC to yield a ratio of five fluorescein 
molecules per molecule of IgG. RA3-2C2 was partially purified from tissue culture supernate 
by precipitation  twice with  40%  saturated  ammonium  sulfate,  followed by  gel filtration on 
Sepharose 6B. This material was either directly conjugated with fluorescein or was used with 
fluorescent  rabbit  anti-rat  Ig.  This  preparation  was  ~25-50%  antibody  and  was  conjugated 
with FITC to a  ratio of 30 fluorescein molecules per molecule of IgM. A rat monoclonal IgM 
with no apparent  cell-binding activity was purified and fluoresceinated in the same way and 
was used as a negative control. Rat anti-mouse Thy-1.2 was obtained from the supernate of the 
hybridoma cell line 30-H12  (6). 
Irnmunofluorescent Staining.  All staining and cell sorting was done in Hanks' basic salts solution 
(BSS) with  10  -a M  sodium azide and 5% fetal calf or calf serum and without phenol red. Bone 
marrow  cell  suspensions  were  prepared  by  flushing  femurs  with  BSS  and  pipetting  the 
suspension  through  a  fine stainless steel screen.  Spleen, lymph node, and thymus suspensions 
were prepared by mincing the organ and pressing it through a  fine screen. All cell suspensions 
were treated with a  solution of 0.155  M  NH4CI, 0.01  M  KHCOa, and  10  -4 M  EDTA to iyse 
erythrocytes. Cell pellets were resuspended at  l0  s cells/ml in the appropriate concentration of 
first or second stage antibody and incubated on ice for 15-30 min. The cell suspension was then 
diluted 20-fold in BSS and centrifuged through a  layer of calf serum. 
Flow Cytomet~y Analysis and Cell Separations.  All flow cytometry and cell sorting was done on 
a fluorescence-activated cell sorter (FACS III, Becton-Diekinson Electronic Laboratories, Moun- 
tain View, Calif.). Viable and nonviable cells were discriminated on the basis of light scatter 
(7) and only the fluorescence of viable cells was considered. Cell sorting was performed at a rate 
of 2,000-3,000  cells/s. Positive and negative gates were separated by  10-15 channels in order 
to  improve the purity  of the fractions.  Negative fractions contained  1-3%  positive cells and 
positive  fractions  contained  2-8%  negative cells.  Cells  were  maintained  at  0°C  in  10 -s  M 
sodium  azide throughout  the sorting  procedure.  "Panning"  on antibody-coated  petri  dishes 
was done by the procedure of Wysocki and Sato (8).  For the removal of B cells, 100-cm dishes 
were coated with 20 ~g each of rabbit anti-p, and anti-g. Purified RA3-2C2 was used at 50 #g/ 
dish for panning. 
In  Vitro  Cultures.  Cells were cultured  for 2  d  at  a  density of 5  ×  106 cells/ml in  Iscove's 
medium (gift of Dr. J. D. Watson, University of California, Irvine) plus  10% fetal calf serum. 
Cells were  plated  in 0.2-ml  tissue  culture  wells and  grown  in  8%  CO2.  Dead  cells in  these 
cultures exhibited significant autofluorescence and nonspecific fluorescent staining and could 
not be satisfactorily gated out on the FACS. As a consequence, stained cultures were scored in 
a fluorescence microscope where live and dead cells could be resolved on the basis of morphology 
and staining pattern.  At least 600 cells were counted for each sample. Tetramethylrhodamine 
isothiocyanate  (TRITC)  labeling of cells was  done  as  described  previously by  Butcher  and 
Weissman  (9). 
Spleen  Colony-forming  Unit Assay.  This assay was performed essentially as described by Till 
and McCulloch (10).  BALB/c mice were given 850 rad of x-ray irradiation before intravenous 
injection of bone marrow cells. 
Plaque-forming  Cell Assay.  Plaque-forming cells to sheep  erythrocytes  were enumerated  by 
the method of Mishell and  Dutton  (11).  IgG plaques were developed by adding rabbit  anti- 
mouse Ig to the complement solution.  Mice were immunized intraperitoneally with 0.2 ml of 
10% sheep erythrocytes 5 d before use for the primary response, and 60 d and again 5 d before 
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Results 
Production ofRA3-2C2 Monoclonal Antibody.  The monoclonal antibody RA3-2C2 was 
selected from the products of a  fusion of mouse myeloma cells with spleen cells from 
a  rat  immunized  with  the  cell  line  RAW  112.  RAW  112  is  an  Abelson  murine 
leukemia  virus-induced  tumor  with  a  pattern  of responsiveness to  B  cell  mitogens 
which suggests it is a  pre-B cell tumor (12). Tumor cells were used as the immunogen 
in preference to normal tissues in order to provide a  relatively enriched source of pre- 
B  cell antigens. 
Fused cells were plated with HAT  selection medium in  1.5-ml tissue culture wells 
and  grown  until  the cells reached  at  least  2  ×  10  ~ cells per well.  The  supernatant 
fluids were then harvested and screened by immunofluorescent staining of RAW  112 
cells. All positive supernatant  fluids were  further  examined  by immunofluorescent 
staining and  FACS analysis on  normal  bone  marrow  and  thymus  cell suspensions. 
RA3-2C2 was selected for further study because it stained only 30% of bone marrow 
cells and did not stain thymocytes. 
The RA3-2C2 antibody was shown serologically to be an IgM and by gel filtration 
to be a polymeric (probably 19s)  Ig molecule. No detectable amount of mouse It-chain 
was incorporated into the active molecule. The antibody bound well to Staphylococcus 
aureus bacteria  and  purified  protein  A  at  pH  7.2,  and  these  could  be  used  for, 
respectively, immunopreeipitation with  and  purification of RA3-2C2  (R.  Coffman, 
unpublished results). 
Immunofluorescent Staining of Lymphoid Tissue with RA3-2C2.  The percentages of cells 
that stain with RA3-2C2 in lymphoid tissues is shown in Table I. The percentages of 
cells positive with anti-It (B cells) or anti-Thy  1 (T cells) are shown  for comparison. 
The monoclonal antibody was used either as a  direct fluorescein conjugate or with a 
fluorescent rabbit anti-rat Ig second stage. A  rat IgM monoclonal antibody with no 
detectable cell binding activity was used as a control for both one-stage and two-stage 
immunofluorescent stainings. Controls usually contained  1-3% of cells in the positive 
channels. RA3-2C2 stains approximately the same number of cells as anti-~¢ in spleen 
and lymph nodes, but stains ~20% more than anti-x in the bone marrow. No staining 
was detected in the thymus. The median fluorescence intensity of RA3-2C2 on spleen 
and lymph node cells is about twice that on bone marrow cells. 
TABLE  I 
Immunofluorescent Staining of Lymphoid Organs with RA3-2C2 
Cell suspension from 
Cells stained with* 
RA3-2C2:~  Anti-r  Anti-Thy-  1 
%  %  % 
Bone marrow  32  10  2 
Spleen  45  52  28 
Lymph node  18  19  67 
Thymus  0  0  97 
* Percent-positive cells minus percent-positive in negative controls (see Mate- 
rials and Methods). Negative controls ranged from I to 3% positive. 
:~ Spleen and lymph nodes were stained with fluorescein-conjugated RA3-2C2. 
All other stains were done with fluorescein-conjugated rabbit anti-rat Ig or 
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Fio.  1.  Immunofluorescent staining of bone marrow ceils with RA3-2C2.  (A) Bone marrow cells 
stained with RA3-2C2 plus fluorescein-conjugated  rabbit anti-rat Ig (upper curve) compared with 
cells stained with a  control rat IgM plus the same second stage.  (B)  Two-parameter display of 
fluorescence intensity vs. light scatter  (which is approximately proportional to cell size). Each dot 
represents the data for a single cell. 
The  staining profile of RA3-2C2  on bone marrow  cells is shown in Fig.  1A, with 
the  control  staining shown  for  comparison.  There  is  a  clear  bimodal  distribution 
which  permits  reasonably  accurate  enumeration  and  separation  of  positive  and 
negative fractions. A  two-parameter "dot-plot" of fluorescence vs. light scatter (which 
is approximately proportional to size in bone marrow cells) shows that both large and 
small cell fractions include RA3-2C2  + cells (Fig.  1B). 65-75% of the RA3-2C2  + bone ROBERT  L.  COFFMAN AND IRVING L.  WEISSMAN  273 
marrow cells are in the small cell fraction, with the remainder being in the medium 
to large cell fraction. The morphology of RA3-2C2 + bone marrow cells was analyzed 
by staining cytocentrifuge  smears  of FACS-purified cells with  Wright's stain.  The 
RA3-2C2 + fraction was 68% small lymphocytes, and 25% medium to large blast cells. 
The  remaining  7%  included  a  variety of other cell types and  probably represented 
RA3-2C2- contaminants because the RA3-2C2 + fraction contained 8% negative cells. 
The  RA3-2C2-  fraction  was  significantly depleted of lymphocytes;  thus,  RA3-2C2 
detects an antigen on most bone marrow lymphocytes. 
RA3-2C2  Is on All B  Cells and a  Fraction  of sIg-  Bone  Marrow Cells.  The preceding 
results suggested that RA3-2C2 recognized primarily B cells and, in the bone marrow, 
might  also  include B  cell precursors.  To  test  this, sIg- and  RA3-2C2-  fractions of 
spleen and bone marrow were isolated by cell sorting, then restained with anti-r or 
RA3-2C2  (Table II). Removal of the sIg  ÷ cells from the spleen removes virtually all 
RA3-2C2 + cells, and at the same time removal of the RA3-2C2 ÷ cells removes all sIg  + 
cells. Therefore, in the spleen, all B  cells are RA3-2C2 ÷ and all RA3-2C2 + cells are B 
cells. In  the bone  marrow,  removal of RA3-2C2 + cells also removes all B  cells, but 
removal of sIg  +  cells leaves a  population  that  is still  19%  RA3-2C2 +.  In summary, 
~ 10% of bone marrow cells are B cells and nearly all are small lymphocytes. Another 
10-12% of bone marrow cells are small sIg-, RA3-2C2 + lymphocytes, and 8-10% are 
medium to large sIg-, RA3-2C2 + cells. 
RA3-2C2 +, sIg-  Bone Marrow  Cells Include  B  Cell Precursors.  To  demonstrate  that 
the RA3-2C2 +, sIg- bone marrow fraction included B cell precursors, we used a short- 
term in vitro culture system in which B  cells arise from sIg- precursors. Briefly, bone 
marrow cells are depleted of sIg  + cells by panning on petri dishes coated with anti-# 
and  anti-x  antibodies  (8).  The  nonadhering  sIg-  cells  were  cultured  in  Iscove's 
medium plus 10% fetal calf serum for 2 d, then stained with a  mixture of rabbit anti- 
# and anti-K to detect newly formed B cells. The mixture of anti-K and anti-# was used 
to  increase  the  staining  intensity  and  make  visual  scoring  of positive  cells  more 
sensitive and accurate. In some experiments, aliquots were also stained with anti-x or 
TABLE II 
Immunofluorescent Staining of slg- and RA3-2C2- Spleen and Bone Marrow 
Cells 
Cell fraction 
Cells stained with* 
Anti-x  RA3-2C2:]: 
%  % 
Unseparated spleen cells  44  40 
slg- spleen cells  2  4 
RA3-2C2- spleen cells  1  3 
Unseparated bone marrow cells 
sIg- bone marrow cells 
RA3-2CT bone marrow cells 
10  27 
0  19 
0  3 
* Percent-positive cells minus percent-positive in negative controls in sorted 
fractions, the negative control includes 1-2% positive contaminants  in addi- 
tion to nonspecific staining of negative cells, which was 1-3% positive. 
:~ Spleen  cell  fractions  were  stained  with  fluorescein-conjugated  RA3-2C2, 
bone marrow fractions with a fluorescein-conjugated rabbit anti-rat Ig. 274  B CELL AND  B CELL  PRECURSOR  SPECIFIC  ANTIBODY 
anti-# alone. In all cases, the percent of positive cells was within  10% of the percent 
positive with  the  mixture of antisera,  demonstrating that  most  sIg  +  cells expressed 
both/z- and re-chains. 
When the RA3-2C2 + cells are removed from sIg- bone marrow by cell sorting, this 
B  cell precursor activity is removed  (Table III). Stained but  unsorted cultures give 
rise to normal numbers of B  cells, so the staining procedure is not responsible for the 
loss of precursor activity. When RA3-2C2 + cells are removed from Ig- bone marrow 
by a  subsequent  panning on purified RA3-2C2-coated petri dishes, B  cell precursor 
activity is eliminated from the unbound fraction. This procedure causes less celt death 
and suggests that the process of sorting does not preferentially kill B  cell precursors. 
Attempts to  culture  the purified RA3-2C2 +, sIg-  fraction  have  been  less successful 
because, when purified, these cells usually die within 2 d  in vitro. This suggests that 
either  an  RA3-2C2-  accessory cell  is  necessary  for  the  survival,  and  possibly the 
differentiation, of the RA3-2C2 ÷ cells, or that the B cell precursors are RA3-2C2- but 
require an RA3-2C2 + accessory cell for their differentiation to proceed. To test these 
possibilities, sIg- and  RA3-2C2-,  sIg- bone  marrow  cells were  marked  by labeling 
with TRITC  (9)  and the labeled cells were then cultured with a  threefold excess of 
unlabeled sIg- bone  marrow  cells. After 2  d,  the cultured cells were stained with  a 
mixture of anti-/~ and anti4¢, followed by a  fluorescein-conjugated second stage, and 
the positive cells were counted both for the unlabeled and the TRITC-labeled cells. 
For comparison, portions of the same fractions were  cultured without  labeling and 
mixing. RA3-2C2-, sIg- cells do not differentiate into B cells even in the presence of 
unlabeled  RA3-2C2 +  cells  (Table  IV).  That  these  cultures  do  provide  the  proper 
environment for this differentation is shown by the fact that the unlabeled sIg- bone 
marrow  cells in  the same cultures give rise to the expected percentage of sIg  + cells. 
This experiment demonstrates that removal of the RA3-2C2 + cells from the sIg- bone 
marrow removes the B cell precursors themselves and not just accessory cells. TRITC 
conjugation  does  not  interfere  with  this  B  cell  differentiation  because  cultures  of 
labeled sIg- cells give rise to the expected number of B  cells either in mixed culture 
(Table IV) or when cultured alone (data not shown). 
RA3-2C2 Does Not  Recognize  the  Pluripotent  Hematopoietic  Stem  Cell.  The  RA3-2C2 
determinant would be especially useful if it were expressed only on cells committed to 
the B  cell lineage and not on the pluripotent stem cell from which B cells, as well as 
TABLE  III 
Bone Marrow Cells that Express sIg in  Vitro Are RA3-2C2 ÷ and sIg- 
Cell fraction 
Ig- bone marrow 
Ig- bone marrow, stained with 2C2 
Ig-, 2C2- bone marrow, sorted 
Ig-, 2C2- bone marrow, panned 
Cells stained with* 
Anti-#  Anti-KLH:]: 
+ Anti-x 
%  % 
I0.3  1.4 
10.5  2.1 
0  0 
1.4  1.2 
* Cells were stained and counted after 2 d in vitro. At least 600 viable cells 
were counted  in  each  sample. The data are pooled  from three  separate 
experiments. 
:~ Control for nonspecific staining. ROBERT  L.  COFFMAN AND  IRVING  L,  WEISSMAN 
TABLE  IV 
B Cell Precursors, Rather than Accessory Cells, Are Absent in RA3-2C2- Bone Marrow 
Cells 
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Cell fraction 
Unlabeled  Rhodamine-labeled cell frac- 
cell fraction  tion* +  unlabeled Ig- bone 
cultured  marrow cells 
alone 
Labeled cells  Unlabeled 
Ig+-BKG:~  Ig+-BKG  cells Ig+-BKG 
Ig- bone marrow 
Ig- RA3-2C2- bone marrow, sorted 
Ig- RA3-2C2- bone marrow, panned 
%  %  % 
8.4  11.0  7.6 
0  0  10.8 
0.8  1.5  9.1 
* The cell fraction was split with one portion being cultured without labeling or mixing, and 
the other portion being labeled with TRITC and mixed on a  1:3 ratio with unlabeled Ig- 
bone marrow cells. All cultures were maintained at 5 ×  108 total cells/ml. 
:]: Percent of cells stained with a mixture of anti-# and anti-K minus the percent stained with 
anti-KLH. 
TABLE V 
CFU-s Cells Are RA3-2C2- 
Mice restored with 
CFU-s* 
Experiment 1  Experiment 2 
105 bone marrow cells  53 ±  2 
105 bone marrow cells, stained with  39 ±  7 
RA3-2C2 and rabbit anti-rat Ig 
3 x  104 RA3-2C2 positive bone mar-  5 ±  1 
row cells 
6  X  104  RA3-2C2  negative  bone  45 ±  5 
marrow cells 
47±6 
41  +  10 
1±1 
43±9 
* Each group comprised four-six recipient spleens. 
TAaLE  VI 
RA3-2C2 Stains Most Plaque-forming Cells 
Plaque-forming cells/108 cells 
Cells  Primary response  Secondary re- 
sponse IgG 
IgM plaques*  plaques:~ 
Unsorted spleen  900  450 
RA3-2C2 + spleen  1,170  980 
RA3-2C2- spleen  430  160 
* Animals were immunized with sheep erythrocytes 5 d before sacrifice. 
:]: Animals were immunized with sheep erythrocytes 60 and 5 d before sacrifice. 
other hematolymphoid  cells, derive (13). This was tested by sorting bone marrow into 
RA3-2C2  positive  and  negative  fractions  and  assaying  each  for  the  presence  of 
CFU-s  (10).  Sorting  gates  were  set  so  that  10  channels  at  the  boundary  between 
positive and negative staining were not included in either fraction. This was done to 
obtain suitable purity of the sorted fractions and resulted in the loss of 5-7% of the 276  B CELL AND B CELL PRECURSOR  SPECIFIC ANTIBODY 
cell suspension. Lethally irradiated mice were injected with  105 bone marrow cells or 
the RA3-2C2 positive or negative fractions from 105 bone marrow cells, and the spleen 
colonies were counted 9 d  later. As shown in Table V, virtually all CFU-s are found 
in  the  RA3-2C2-  fraction.  Stained  but  not  sorted  bone  marrow cells  do  not  have 
significantly reduced numbers of CFU-s;  their absence in the positive fraction is not 
due to inhibition by the antibody. 
RA3-2C2 Recognizes Most Plasma Cells.  The recognition by RA3-2C2 of the terminal 
stage of the B cell lineage, the plasma cell was tested by sorting RA3-2C2 positive and 
negative fractions from sheep erythrocyte-primed spleen cells. The number of sheep 
erythrocyte-specific antibody-forming cells  in  each  fraction was determined  by the 
Jerne  plaque-forming cell  assay.  The  results  of one of three  such  experiments  are 
shown in Table VI. RA3-2C2 appears to recognize the majority of primary IgM and 
secondary IgG plaque-forming cells, but there are significant numbers of each in the 
RA3-2C2- fraction.  The presence of plaque-forming cells in the RA3-2C2-  fraction 
is not due to contamination by RA3-2C2 ÷ cells, since both negative fractions contained 
only  1%  RA3-2C2 ÷.  This  may indicate  a  significant  heterogeneity  among plasma 
cells, or it may mean that plasma cells generally bind less RA3-2C2 than B cells, and 
some of them bind too little to be resolved from RA3-2C2- cells. 
Discussion 
The determinant  recognized by the monoclonal antibody,  RA3-2C2,  is expressed 
on a spectrum of cell types within the B cell lineage. At the same time, its expression 
appears to be restricted  largely, if not  entirely,  to the B  lineage.  It is expressed on 
more cell types than other commonly used B cell markers such as sIg and Ia, and may 
prove to be a more useful marker for members of this lineage. Some care is necessary, 
however, to get accurate staining percentages, especially when the analysis is done by 
flow  cytometry.  Perhaps  because  the  antibody  is  a  multivalent  IgM,  it  causes 
significant agglutination of some positive cells when used with an anti-rat Ig second 
stage. Flow cytorneters, such as the FACS, filter out these aggregates so they cannot 
clog the nozzle orifice, and the remaining single-cell suspension is therefore relatively 
depleted  of positive cells.  For  example,  until  this  artifact  was  noticed,  spleen  cell 
suspensions appeared to be only 20% RA3-2C2 + on the FACS. The problem can be 
minimized by using directly fluoresceinated monoclonal antibody and resuspending 
the cells immediately before analysis.  The phenomenon  is observed primarily with 
spleen and lymph node cells, and little,  if any, agglutination  is observed with bone 
marrow cells. 
Approximately 10% of nucleated  bone marrow cells are RA3-2C2 ÷, sIg  + lympho- 
cytes. Another 20% of bone marrow cells are RA3-2C2 +, sIg-, and are predominantly 
lymphoid in morphology. The total lymphoid compartment of adult  bone marrow 
has been estimated  by others  to consist  of about  25%  of nucleated  cells  (14),  with 
approximately equal numbers of sIg  + and sIg- small lymphocytes (15,  16).  Further- 
more, the number of B cell precursors, as measured by the presence of cytoplasmic 
chains,  is approximately equal to the number of slg  + B  cells  (17).  These estimates, 
from  a  number  of laboratories,  are  consistent  with  the  estimate  of the  lymphoid 
compartment as judged by the RA3-2C2 ÷ cells. At least two types of cells are present 
in  the sIg-, RA3-2C2 + bone marrow fraction.  The majority are small lymphocytes 
which  comprise  50-60%  of the  sIg-,  RA3-2C2 ÷  fraction,  while  the  remainder  are ROBERT  L. COFFMAN AND IRVING L. WEISSMAN  277 
larger cells with  morphologically undifferentiated  nuclei  and  relatively little  cyto- 
plasm. These larger cells most likely include the transitional lymphoid cells described 
by Miller and Osmond  (14), but  they may include  immature stages in other hema- 
topoietic lineages as well. Both small and large sIg- lymphoid populations have been 
shown  to include  cells containing cytoplasmic ~-ehains  (17).  Although  the labeling 
kinetics of these two cell types were consistent with the idea that the larger cell is a 
precursor for the smaller one, a direct precursor-product relationship between the two 
cell types has not yet been demonstrated. 
The in vitro culture system for the generation of B cells from B cell precursors is 
very  similar  to  ones  described  previously  (15,  18,  19).  It  seems  likely  that  only 
relatively mature precursors give rise to sIg  + cells under these conditions. Most of the 
B cells are generated within the first 24 h and most of the activity resides in the small 
cell  fraction  of bone  marrow  (R.  Coffman,  unpublished  results).  B  cell  precursor 
activity has been demonstrated in large bone marrow cells as well, but the differen- 
tiation of these cells into antigen- or mitogen-responsive B cells requires 4-5 d in vitro 
(20)  and possibly longer in vivo (21). 
Direct fluorochrome conjugation of cells has been used in our laboratory to study 
lymphocyte homing and thymus cell maturation.  These studies show that FITC or 
TRITC  conjugation  of lymphoid  cells  does  not  impair  either  specific  lymphocyte 
migration (22) or graft vs. host reactivity (9).  Similarly, TRITC conjugation does not 
impair the ability of B cell precursors to express sIg. After 2 d, some loss of TRITC 
occurs, but all cells that were initially labeled can still be readily detected. 
The RA3-2C2 determinant is not expressed on the pluripotent hematopoietic stem 
cell,  suggesting that  it  is expressed later in  the differentiation pathway, perhaps at 
about the same time as the commitment to the B  cell lineage. This assumes that B 
cells derive from the same cell which gives rise to the spleen colonies. This assumption 
is supported by studies in which unique, radiation-induced, chromosome markers are 
found both in spleen colonies and in T  and B  cell blasts (13).  Although  B cells are 
rare in spleen colonies, Lala and Johnson have shown that they are part of the same 
clone as the rest of the colony (23). 
The nature of the surface molecule bearing the RA3-2C2 determinant is unclear at 
present. RA3-2C2 precipitates a  50,000-mol wt molecule (P50)  from biosynthetically 
labeled bone marrow, spleen, thymus cells, and from Abelson murine leukemia virus- 
transformed cell lines (24). The synthesis of this protein is greatly increased in some 
transformed cells and  is expressed by many nonlymphoid tumors as well.  It is  not 
known, however, whether the P50 molecule is expressed on the cell surface, because 
no  P50  is  detectable  in  immunoprecipitates  of lactoperoxidase-catalyzed  surface- 
radioiodinated cells. 
The reason for producing monoclonal antibodies directed against pre-B tumors was 
to isolate antibodies to determinants on normal B cell precursors. The ideal antibody 
would perhaps be one that was specific for these precursors and did not recognize sIg  + 
B  cells,  but  no such  antibody has been found  in  three  fusion  experiments.  For the 
purposes of enumerating  and  isolating  pre-B cells,  however,  the  B  lineage  specific 
antibody  described  here  may be just  as  useful.  More  than  90%  of B  cells  can  be 
routinely removed from bone marrow by the rapid and gentle technique of panning 
on anti-p- and anti-K-coated petri dishes. When necessary, even better depletions of B 
cells  can  be achieved with  the  FACS.  After  depletion  of sIg  +  cells  from the  bone 278  B CELL AND B CELL  PRECURSOR  SPECIFIC ANTIBODY 
marrow,  the remaining RA3-2C2 + cells appear to be  largely, if not  entirely, B  cell 
precursors.  These  cells  can  then  be  isolated  with  90-95%  purity  on  the  FACS. 
Experiments  to examine Ig biosynthesis and  Ig gene organization in  these cells are 
currently in progress. 
Summary 
The monoclonal antibody, RA3-2C2,  appears to be specific for cells within the B 
cell  lineage.  This  antibody  does  not  recognize  thymocytes,  peripheral  T  cells,  or 
nonlymphoid hematopoietic cells in the spleen or bone marrow. Nor does it recognize 
the pluripotent hematopoietic stem cells, the spleen colony-forming unit.  All sIg  + B 
cells and  most  plasma  cells are  RA3-2C2 ÷.  In  addition,  ~20%  of nucleated  bone 
marrow cells are RA3-2C2 + but sIg-. This population contains B cell precursors that 
can give rise to sIg  + cells within 2 d  in vitro. 
We wish to thank Francis Assisi and Trygve Statte for their excellent assistance on the FACS. 
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